All In Biotech

Drug Trial Radar · NCT06090721

DMT310-009 Topical in the Treatment of Acne Vulgaris

A PHASE 3 STUDY OF TOLERABILITY, SAFETY, AND EFFICACY, OF DMT310 IN PATIENTS WITH ACNE VULGARIS

Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

520

Actual

Start

Dec 8, 2023

Primary completion

Mar 31, 2025

Study completion Apr 30, 2025

Sponsor

Lead sponsor
Dermata TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris

Conditions

  • Acne Vulgaris

Interventions

  • DMT310Drug

    Topical Powder

  • PlaceboDrug

    Placebo Topical Powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy as measured by lesion countsTime frame: 12 weeks
  2. Efficacy as measured by Investigator Global Assessment (IGA)Time frame: 12 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Dermatology Clinical Research, Inc.

    Freemont, California

  • DermResearch

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.